Activation of AMPK/mTOR-Driven Autophagy and Suppression of the HMGB1/TLR4 Pathway with Pentoxifylline Attenuates Doxorubicin-Induced Hepatic Injury in Rats

• Main Authors: Hany H. Arab (Author), Ahmed H. Eid (Author), Shuruq E. Alsufyani (Author), Ahmed M. Ashour (Author), Alwaleed M. Alnefaie (Author), Nasser M. Alsharif (Author), Abdullah M. Alshehri (Author), Abdulmajeed A. Almalawi (Author), Abdulmajeed A. Alsowat (Author), Hayat A. Abd El Aal (Author), Eman S. G. Hassan (Author), Wessam H. Elesawy (Author), Alzahraa A. Elhemiely (Author)
• Format: Book
• Published: MDPI AG, 2024-05-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Despite being an effective chemotherapeutic agent, the clinical use of doxorubicin (DOX) is limited by several organ toxicities including hepatic injury. Pentoxifylline (PTX) is a methylxanthine derivative with marked anti-inflammatory and anti-apoptotic features. It is unknown, however, whether PTX...